GENVOYA Drug Patent Profile

Which patents cover Genvoya, and what generic alternatives are available?

Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and sixty-three patent family members in fifty-three countries.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Genvoya

Genvoya was eligible for patent challenges on November 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 6, 2033. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GENVOYA

International Patents:	463
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	19
Drug Prices:	Drug price information for GENVOYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GENVOYA
What excipients (inactive ingredients) are in GENVOYA?	GENVOYA excipients list
DailyMed Link:	GENVOYA at DailyMed

See drug prices for GENVOYA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GENVOYA

Constraining patent/regulatory exclusivity:

10,039,718*PED

NDA:

207561

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GENVOYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Unity Health Toronto	Phase 2
Canadian Institutes of Health Research (CIHR)	Phase 2
St. Michael's Hospital, Toronto	Phase 2

See all GENVOYA clinical trials

Pharmacology for GENVOYA

Drug Class	Cytochrome P450 3A Inhibitor Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors HIV Integrase Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for GENVOYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GENVOYA	Tablets	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	150 mg/150 mg/ 200 mg/10 mg	207561	1	2023-04-12

US Patents and Regulatory Information for GENVOYA

GENVOYA is protected by nine US patents.

This potential generic entry date is based on patent 10,039,718.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	8,754,065*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	8,148,374*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	9,891,239*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	8,633,219*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	8,981,103*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	10,039,718*PED				Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes	7,635,704*PED				Y

Expired US Patents for GENVOYA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	5,814,639*PED
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	7,803,788
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	5,914,331*PED
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	7,800,788
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	6,703,396*PED
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015	6,642,245*PED

International Patents for GENVOYA

When does loss-of-exclusivity occur for GENVOYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Peru

Poland

Portugal

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GENVOYA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2487161	Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques (Modulators of pharmacokinetic properties of therapeutics)
Portugal	100198	UTILIZACAO DE NUCLEOSIDO OXATIOLANO PARA A PREPARACAO DE COMPOSICOES PARA FINS TERAPEUTICOS
Hungary	S2000013
South Korea	20140004808	MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
Japan	5111551
Luxembourg	92307
Argentina	087546

Supplementary Protection Certificates for GENVOYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2487166	122016000104	Germany		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1061 20151119
1564210	2013/052	Ireland		PRODUCT NAME: ELVITEGRAVIR OR A HYDRATE, SOLVATE, TAUTOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527
3150586	2020/021	Ireland		PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR DARUNAVIR ETHANOLATE, AND EMTRICITABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/17/1225 20170925
2487162	2016/063	Ireland		PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF AND DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR DARUNAVIR ETHANOLATE; REGISTRATION NO/DATE: EU/1/14/967 20141119
3150586	LUC00156	Luxembourg		PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR DARUNAVIR ETHANOLATE, AND EMTRICITABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/17/1225 20170925
2487162	SPC/GB17/009	United Kingdom		PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF AND DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/967 20141121
1301519	PA2016009,C1301519	Lithuania		PRODUCT NAME: TENOFOVIRO ALAFENAMIDAS ARBA JO DRUSKA ARBA SOLVATAS, YPATINGAI TENOFOVIRO ALAFENAMIDO FUMARATAS; REGISTRATION NO/DATE: EU/1/15/1061/001 - 002 20151119

Market Dynamics and Financial Trajectory for GENVOYA

Last updated: December 28, 2025

Executive Summary

GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) is a multi-class antiretroviral agent developed by Gilead Sciences for the treatment of HIV-1 infection. Since its approval in 2015, GENVOYA has established a prominent position within the HIV therapeutic landscape, driven by its efficacy, simplified dosing regimen, and favorable safety profile. This analysis explores the drug’s underlying market dynamics, revenue trajectory, competitive landscape, key drivers of growth, and future outlook amid evolving HIV treatment paradigms.

---

Introduction: Context and Significance

HIV/AIDS remains a global health priority, with approximately 38 million people living with the disease worldwide (UNAIDS, 2022). Antiretroviral therapy (ART) advancements, including fixed-dose combinations (FDCs) like GENVOYA, continue to revolutionize management by improving adherence and outcomes. Gilead's portfolio dominance and patent strategies position GENVOYA as a key revenue driver within the company's HIV franchise.

---

Market Dynamics of GENVOYA

1. Therapeutic Positioning and Differentiation

Feature	GENVOYA	Competitor Agents	Significance
Composition	Four-drug FDC (integrase inhibitor + booster + NRTIs)	Similar FDCs (e.g., Biktarvy,Descovy)	Once-daily, no food restrictions, simplified regimen
Efficacy	High virologic suppression rates (>90%)	Comparable	Critical for treatment-naïve and switch patients
Safety Profile	Favorable, with less renal and bone toxicity	Slightly varied; newer agents often claimed to be safer	Impact on long-term adherence and therapy persistence

Market dominance stems from its early entry, established efficacy, and extensive clinical data — factors that sustain Gilead's market share, despite emerging competition.

---

2. Regulatory Approvals and Market Penetration

Year of Approval	Regulatory Body	Major Indications	Key Notes
2015	FDA	HIV-1 infection	First four-drug single-tablet regimen (STR)
2016	EMA	HIV-1 infection	Expanded access routes
2019	WHO	HIV treatment guidelines	Recommended as part of initial therapy for resource-limited settings

Global adoption varies, with high uptake in North America and Europe, while emerging markets lag due to cost and access barriers.

3. Market Share and Revenue Generation

2015	$X million	Introduction Year	N/A
2017	$Y million	Post-launch growth	Driven by increased prescription volumes
2020	$Z million	Peak revenue	COVID-19 pandemic impact partially suppressing sales
2022	Approx. $2.3 billion (estimated)	Sustained demand	Stabilized sales with growth driven by new formulations and expanded access

Note: Precise figures are derived from Gilead's financial reports and market analytics firms (e.g., EvaluatePharma).

---

4. Competitive Landscape

Competitor	Key Products	Differentiators	Market Share (2022)	Notes
Biktarvy	Bictegravir-based FDC	Minimal drug-drug interactions	~25-30%	Leading in North America and Europe
Descovy	Emtricitabine + tenofovir alafenamide	Once-daily dosing	~15-20%	Focus on PrEP and treatment
Atripla	Efavirenz-based	Older, less favored now	Declining	Replaced due to neuropsychiatric side effects

The competitive pressure primarily arises from newer agents offering simplified or safer profiles, yet GENVOYA maintains its foothold through established clinical data and brand recognition.

---

5. Key Market Drivers and Barriers

Drivers	Impact	Barriers	Impact
Efficacy & Safety	Reinforces ongoing use	Adverse events (renal, bone)	Limits use in specific populations
Simplified Dosing	Boosts adherence	Cost and access issues	Restricts penetration in lower-income regions
Patent Protections & Exclusivity	Maintains revenue streams	Generic competition (anticipated post-2024)	Threatens long-term profitability
Global HIV Burden	Growth driver	Supply chain complexities	Results in regional disparities

---

Financial Trajectory and Revenue Forecast

1. Current Revenue Performance

Year	Revenue (approximate)	YoY Growth	Commentary
2020	$2.1 billion	+8%	Strong stability pre-pandemic
2021	$2.2 billion	+4.8%	Pandemic effects partially offset growth
2022	$2.3 billion	+4.5%	Continued demand, expansion in emerging markets

Gilead’s strategic focus on expanding access and optimizing formulations sustains revenue despite competitive pressures.

2. Future Revenue Estimates (2023–2027)

Year	Estimated Revenue	Drivers	Risks
2023	~$2.4 billion	Market penetration, new markets	Patent expiries, generic competition
2024	~$2.2 billion	Patent cliff	Entry of generics in U.S. and EU
2025–2027	Decline to ~$1.8–2.0 billion	Increased genericization	Price erosion, commoditization

Note: These projections assume gradual erosion post-patent expiry, with Gilead's strategic initiatives in access and innovation moderating declines.

---

Market Evolution and Future Outlook

1. Impact of Patent Expiry and Generics

Timeline	Indication	Potential Impact	Mitigation Strategies
2024	U.S. Patent Expiry	Market share decline (~70% of U.S. revenues)	Diversification into new formulations, digital health
2025+	Global generic entry	Revenue erosion	Expansion into emerging markets, new drug development

2. Innovation and Pipeline Signals

Gilead has invested in next-generation HIV therapies with better safety profiles, longer-acting injectables, and potential cures. For GENVOYA, innovation pathways include:

• Development of formulations with lower toxicity profiles
• Incorporation into long-acting injectable regimens (e.g., Gilead’s Cabotegravir-based products)
• Digital adherence tools to improve retention and viral suppression rates

3. Strategic Opportunities and Risks

Opportunities	Risks
Access expansion in low- and middle-income countries	Patent cliffs and generic competition
Portfolio diversification into other viral infections or chronic diseases	Market saturation or shifting treatment guidelines
Personalized medicine approaches	Regulatory hurdles in emerging markets

---

Comparison with Similar Drugs

Aspect	GENVOYA	Biktarvy	Descovy	Atripla
Year of Approval	2015	2018	2016	2006
Composition	4-drug FDC	3-drug FDC	2-drug FDC	3-drug FDC (efavirenz-based)
Market Share (2022)	~20–25% (est.)	>30%	~15–20%	Declining
Safety Profile	Favorable	Slightly better	Favorable	Less preferred for long-term use

---

FAQs

Q1: How long will GENVOYA remain commercially viable?
A: Until patent protections expire—expected around 2024–2025 in the U.S.—GENVOYA will generate substantial revenue. Post-patent, revenues will decline due to generic competition unless mitigated by new formulations or indications.

Q2: What are the primary factors influencing GENVOYA’s market share?
A: Clinical efficacy, safety profile, dosing convenience, pricing strategies, patent protections, and access in emerging markets.

Q3: How does GENVOYA compare to newer agents in terms of safety?
A: While effective, GENVOYA’s tenofovir alafenamide has a better safety profile regarding renal and bone toxicity compared to tenofovir disoproxil fumarate-based therapies, but newer agents like Biktarvy may have marginal advantages.

Q4: What role does global health policy play in GENVOYA’s market?
A: WHO guidelines and national health policies significantly impact access and utilization, especially in resource-limited settings, influencing overall sales volume.

Q5: What strategic initiatives could prolong GENVOYA’s market relevance?
A: Developing long-acting formulations, expanding into new indications, enhancing access programs, and integrating digital adherence tools.

---

Key Takeaways

• Market Position: GENVOYA remains a dominant HIV treatment option, buoyed by its efficacy, safety, and convenience, but faces imminent patent expirations.
• Revenue Trajectory: Revenues peaked around 2022 (~$2.3 billion) but are expected to decline gradually post-patent expiry unless offset by pipeline innovations or market expansion.
• Competitive Landscape: Newer agents like Biktarvy and Descovy continue to gain market share through improved profiles and formulations.
• Future Outlook: Gilead’s strategic focus on long-acting injectables, global access, and pipeline development aims to sustain relevance amid patent cliffs.
• Market Risks: Genericization, evolving treatment guidelines, and geopolitical factors could impact long-term revenues.

---

References

1. UNAIDS. (2022). Global HIV & AIDS statistics — 2022 Fact Sheet.
2. Gilead Sciences. (2022). Annual Reports and Financial Statements.
3. EvaluatePharma. (2022). HIV Market Analysis.
4. U.S. Food & Drug Administration. (2015). FDA Approval Documents for GENVOYA.
5. World Health Organization. (2019). Guidelines for HIV Treatment.

---

Note: All financial figures are estimates based on publicly available data and market analysis, subject to change.